Literature DB >> 24135824

[Epistaxis and anticoagulation - a medical and economic challenge?].

C Bermüller1, M Bender2, C Brögger2, F Petereit2, M Schulz2.   

Abstract

BACKGROUND: According to recent statistics more and more elderly patients are hospitalized due to epistaxis and need anticoagulation. Aim of the present study was to investigate if it was more complex to treat anticoagulated patients than non-anticoagulated patients, if these patients needed a longer hospital stay and to characterize the study population in terms of the various applied therapeutic methods.
METHODS: Retrospective study, collecting clinical data of all in-patients treated between 1.1.2007 to 1.8.2011 at an ENT-Department of an University Clinic due to epistaxis.
RESULTS: Of 656 patients 265 were not anticoagulated, 391 were anticoagulated. The mean patients' age increased statistically significant. Patients without anticoagulation were significantly younger than patients with anticoagulation. The duration of the hospitalization differed significantly between the groups, with the longest for patients treated with warfarin (5.4 days). 71 patients underwent surgical treatment of epistaxis (cautery of the sphenopalatine artery or anterior ethmoid artery).
CONCLUSION: During the study period an increasing number of more elderly patients needed hospitalization due to epistaxis. The duration of hospitalization differed significantly between the groups, with longer stays for the anticoagulated patients. Currently, treatment of epistaxis patients however is reimbursed independently of the presence of comorbidities or anticoagulation therapy. For the further development of the German DRG System a new split of the epistaxis DRG should be considered. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24135824     DOI: 10.1055/s-0033-1355400

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  8 in total

1.  [Otorhinolaryngology in the field of demography, growing outpatient care and regionalization].

Authors:  C E Schmidt; T Schuldt; A Kaiser; P Letzgus; J Liebeneiner; K Schmidt; A Öner; R Mlynski
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

2.  Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.

Authors:  Petar Stankovic; Robert Georgiew; Cornelius Frommelt; Sabine Hammel; Jan Wittlinger; Stephan Hoch; Danilo Obradovic; Nikolaos Dagres; Thomas Wilhelm
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 3.  Current Approaches to Epistaxis Treatment in Primary and Secondary Care.

Authors:  Rafael Beck; Martin Sorge; Antonius Schneider; Andreas Dietz
Journal:  Dtsch Arztebl Int       Date:  2018-01-08       Impact factor: 5.594

4.  SUPRAPUR(®): Safe and convenient percutaneous suprapubic catheterisation in high-risk patients.

Authors:  Maximilian Christian Kriegmair; Philipp Mandel; Manuel Ritter
Journal:  Cent European J Urol       Date:  2015-11-25

5.  Hospitalization for epistaxis: a population-based healthcare research study in Thuringia, Germany.

Authors:  Max Kallenbach; Andreas Dittberner; Daniel Boeger; Jens Buentzel; Holger Kaftan; Kerstin Hoffmann; Peter Jecker; Andreas Mueller; Gerald Radtke; Orlando Guntinas-Lichius
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-03-02       Impact factor: 2.503

6.  Treating epistaxis - who cares for a bleeding nose? A secondary data analysis of primary and secondary care.

Authors:  Annina E Althaus; Jonas Lüske; Ulrike Arendt; Michael Dörks; Michael H Freitag; Falk Hoffmann; Kathrin Jobski
Journal:  BMC Fam Pract       Date:  2021-04-15       Impact factor: 2.497

7.  [Epistaxis and anticoagulation therapy: an analysis based on health insurance data from Lower Saxony].

Authors:  A E Althaus; U Arendt; F Hoffmann; J Lüske; M H Freitag; K Jobski; M Dörks
Journal:  HNO       Date:  2021-03       Impact factor: 1.284

8.  The role of oral anticoagulants in epistaxis.

Authors:  A M S Buchberger; A Baumann; F Johnson; N Peters; G Piontek; K Storck; A Pickhard
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-23       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.